BRIEF

on BioNxt Solutions Inc. (CVE:BNXT)

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

BioNxt Solutions Inc., a biopharmaceutical company specializing in drug-delivery technologies, announced advancements in its targeted chemotherapy delivery platform. The technology aims to localize toxic chemotherapy drugs within and around tumors, reducing systemic exposure. Using a dual-action mechanism, it concentrates chemotherapy drugs near tumors and neutralizes drugs outside the tumor to protect healthy tissue. In-vitro tests show a potential tenfold increase in therapeutic effect while safeguarding healthy cells.

The research team has initiated a molecule databank to prioritize chemotherapy drugs for advanced research. A shortlist of high-priority targets has been identified, focusing on a promising drug with notable pharmacokinetic properties used in conventional and targeted oncology treatments.

BioNxt anticipates announcing further research steps and patent strategies soon. The company plans to sign a definitive agreement in the coming weeks.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BioNxt Solutions Inc. news